CardioVascular BioTherapeutics (fka CVBT)

[johnnymcgriffin347]

Zhittya Genesis Medicine Inc. To Compete with a Defunct CVBT

Doing my daily run of research of the biotechnology industry I found interesting news coming from Zhittya Genesis Medicine. It appears that Zhittya is developing a way to treat the damage caused to the lungs of those suffering from COVID-19 and other respiratory diseases which could cause permanent damage to the lungs. How does this compare to what we are doing at CVBT/VT in regards to COVID-19? We already know that in a very short time Zhittya Genesis Medicine Inc has received clinical approvals and always seem to be a step ahead of us. In the last three years they have undoubtedly done more than CVBT/VT with the exception of patents. Will they beat us to this indication as well?

Here are some links to the news regarding Zhittya Genesis Medicine Inc. and COVID-19

https://au.finance.yahoo.com/news/ellis-martin-report-zhittya-genesis-001200535.html

https://www.abnnewswire.net/press/en/100875/zhittya[/url][tag]insert-text-here

www.metalsnews.com/Metals+News/ABNNewswire/ABN+Newswire/MNNEWS1302566/Ellis+Martin+Report+Zhittya+Genesis+Medicines+FGF1+Drug+Might+Be+Potential+RemediationRepair+for+Damaged+Lungs+of+C.htm